The Division of Blood Diseases and Resources (DBDR) is part of the National Heart, Lung, and Blood Institute (NHLBI), one of 27 institutes and centers at the National Institutes of Health (NIH). DBDR supports research on the causes, prevention, and treatment of nonmalignant blood diseases, including anemias, sickle cell disease, and thalassemia; premalignant processes such as myelodysplasia and myeloproliferative disorders; hemophilia and other abnormalities of hemostasis and thrombosis; and immune dysfunction. Funding encompasses a broad spectrum of research ranging from basic biology to medical management of blood diseases.
The Division has a major responsibility for research to assure the adequacy and safety of the Nation's blood supply. The Division also has a leading role in applying scientific advances in transfusion medicine and stem cell biology to the development of new cell-based therapies to repair and regenerate human tissues and organs. DBDR has three branches: the Blood Diseases Branch, the Thrombosis and Hemostasis Branch, and the Transfusion Medicine and Cellular Therapeutics Branch.
BLOOD DISEASES BRANCH
The Blood Diseases Branch supports research and training programs focusing on a wide variety of blood diseases that include sickle cell disease (SCD), thalassemia, Fanconi anemia, Diamond-Blackfan anemia and other aplastic anemias as well as outcomes-related research.
Research in sickle cell disease and thalassemia ranges from elucidating their etiology and pathophysiology to improving disease treatment and management. Areas of emphasis include genetics, regulation of hemoglobin synthesis, iron chelation, development of drugs to increase fetal hemoglobin production, hematopoietic transplantation, and gene therapy. Developing animal models for preclinical studies is another area of interest. Clinical studies in sickle cell disease include identification of risk of complications, prevention of organ damage, development of targeted therapies to increase fetal hemoglobin, and approaches to interrupt vascular damage, thrombosis and inflammatory processes which contribute to morbidity and mortality. NHLBI serves as a coordinating center for hemoglobinopathy research activities at NIH, collaborating with NIDDK, NINDS and NICHD in funding related research.
Harvey Luksenburg, M.D., Acting Branch Chief
THROMBOSIS AND HEMOSTASIS BRANCH
This Branch supports research and training programs on basic research, clinical studies, and technology development in hemostasis, thrombosis, and endothelial cell biology. The main focus is on understanding the pathogenesis of both arterial and venous thrombosis in order to improve diagnosis, prevention, and treatment of thrombosis in heart attack, stroke, and peripheral vascular diseases. A major goal is to find additional platelet inhibitors, anticoagulants, and fibrinolytic agents that will improve specificity and reduce side effects when used in treating thrombotic and thromboembolic disorders. Specialized Centers of Clinically Oriented Research (SCCORS) support collaborative studies on hemostatic and thrombotic disorders.
Finding effective treatments for bleeding disorders is another priority. The Branch supports research on hemophilia and von Willebrand Disease as well as immune disorders such as idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and systemic lupus erythematosus. Emerging areas of interest are gene transfer, clinical proteomics, inflammation and thrombosis, stroke, coagulation activation, autoimmune disease, and thrombotic complications of obesity, diabetes, and cancer.
Donna DiMichele, M.D., Acting Branch Chief
TRANSFUSION MEDICINE AND CELLULAR THERAPEUTICS BRANCH
This Branch supports research and research training in transfusion medicine, stem cell biology and disease, clinical cellular medicine, and blood supply adequacy and safety. Research focus is on the use, safety, and availability of blood and blood components for transfusion and cellular therapies. Research areas include transmission of disease, non-infectious complications of transfusions, immunobiology, cell biology and disease, novel cell-based therapies, hematopoietic stem cell transplantation, and overall product availability. The Branch develops programs for basic and clinical research related to normal and abnormal cellular biology and pathology. It also collaborates with governmental, private sector, and international organizations to improve the safety and availability of the global supply of blood and blood components.
The Branch also supports two clinical research networks to promote efficient comparison of innovative treatment strategies. The Bone Marrow Transplant Clinical Trials Network (BMTCTN) supports trials for patients undergoing blood or marrow transplantation. The Transfusion Medicine/Hemostasis Clinical Trials Network (TMHCTN) supports trials for patients with hemostatic disorders, such as idiopathic thrombocytopenia and thrombotic thrombocytopenic purpura. Specialized Centers of Clinically Oriented Research support collaborative studies on transfusion biology and medicine.
Simone Glynn, M.D., Branch Chief
RESEARCH TRAINING AND CAREER DEVELOPMENT
Designated DBDR scientists are responsible for planning and directing training and career development programs for research in blood diseases and resources. These programs are available for all stages in the professional development of the investigator and include: pre-and post-doctoral training; career development for junior and mid-career faculty, and special training opportunities targeted to special populations.
For further information contact:
W. Keith Hoots, MD, Director
Division of Blood Diseases and Resources
The National Heart, Lung and Blood Institute
Two Rockledge Center, Suite 9030
6701 Rockledge Dr. MSC 7950
Bethesda, Maryland 20892-7950
Additional phone numbers are available in the Abbreviated Staff Directory